Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

Inclusion Criteria:

Histologically or cytologically confirmed colorectal cancer (advanced or metastatic disease not amenable to potential curative resection)
Archival tumor (blocks and/or slides) must be available for patients who decline tumor biopsies
Tumor must be amenable to sequential biopsies for patients willing to undergo tumor biopsy
Must have evidence of disease progression after first-line chemotherapy for advanced disease
Previously irradiated lesions are not considered measurable disease
Measurable disease, defined as >= 1 unidimensionally measurable target lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan
No known brain metastases
Eastern Cooperative Oncology Group (ECOG) 0-2 OR Karnofsky 60-100%
Life expectancy of more than 12 weeks
white blood cell count (WBC) >= 3,000/mm^3
Bilirubin normal
Creatinine normal OR creatinine clearance >= 60 mL/min
No hypertension
No symptomatic congestive heart failure
No unstable angina pectoris
No cardiac arrhythmia
Not pregnant or nursing
Able to swallow oral medication
Willing to undergo 2 sequential tumor and skin biopsies
No ongoing or active infection
No history of allergic reaction attributed to compounds of similar chemical or biologic composition to study drugs
No psychiatric illness or social situation that would preclude study compliance
No other uncontrolled illness
No prior cetuximab
No concurrent prophylactic filgrastim (G-CSF), sargramostim (GM-CSF) or epoetin alfa
At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
No other concurrent chemotherapy
More than 4 weeks since prior radiotherapy and recovered
No prior sorafenib
No other prior therapy targeted against MAPK

More than 14 days since prior and no concurrent administration of the following cytochrome P450 3A4 (CYP3A4) inducers:

Rifampin
Rifabutin
Hypericum perforatum (St. John's wort)
Phenytoin
Carbamazepine
Phenobarbital

More than 7 days since prior and no concurrent administration of the following CYP3A4 inhibitors:

Amiodarone
Clarithromycin
Diltiazem
Erythromycin
Grapefruit juice
Indinavir
Saquinavir
Lopinavir in combination with ritonavir
Fosamprenavir
Ritonavir
Atazanavir
Nelfinavir
Itraconazole
Ketoconazole
Nefazodone
No concurrent combination antiretroviral therapy for HIV-positive patients
No other concurrent investigational agents
No other concurrent anticancer therapy
Negative pregnancy test
Fertile patients must use effective contraception
Absolute neutrophil count >=1,500/mm^3
Platelet count ≥ 100,000/mm^3
No evidence of bleeding diathesis
Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5 times upper limit of normal